Most Read Articles
4 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
5 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Sodium-glucose cotransporter 2 inhibitors pose weak cardiovascular risk in T2D

01 Jul 2020

In Japanese patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 inhibitors (SGLT2is) pose less of a cardiovascular (CV) risk than other glucose-lowering drugs (oGLDs) and dipeptidyl peptidase-4 inhibitors (DPP4is), a new study has shown.

Researchers compared 33,890 T2D patients treated with SGLT2is to the same number of patients receiving oGLDs. At the same time, they compared 9,876 SGLT2i-treated patients to the same number of DPP4i-treated cases. The primary outcome was the risk of developing CV events.

Patients who initiated SGLT2i vs oGLD medications saw a reduced risk of death (hazard ratio [HR], 0.56, 95 percent confidence interval [CI], 0.47–0.69) and of being hospitalized for heart failure (HR, 0.75, 95 percent CI, 0.64–0.89). Taking these two outcomes as a composite also demonstrated the relative superiority of SGLT2i (HR, 0.65, 95 percent CI, 0.58–0.74).

Similarly, stroke was significantly less likely to develop in those who received SGLT2is vs oGLDs (HR, 0.66, 95 percent CI, 0.52–0.84).

SLGT2is also conferred lower risks of death (HR, 0.52, 95 percent CI, 0.36–0.73) and its composite with hospitalization for heart failure (HR, 0.65, 95 percent CI, 0.51–0.83), as compared with DPP4is.

“Future analyses comparing SGLT2i and oGLD/DPP4i initiators from different patient backgrounds, such as patients with/without metformin, with/without multiple CV risk factors, with lower body mass index, and with established CVD might provide more insight into the potential CV benefits of SGLT2i,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 4 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
5 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.